Abstract
Objective: To evaluate the influence of cardiometabolic comorbidities on the evolution of Coronavirus Disease 2019 (COVID-19) in patients with Systemic Lupus Erythematosus (SLE) in Amazonas. Methods: Prospective, observational and descriptive study, part of the umbrella project REUMACOV BRASIL. The records of patients with SLE from the REUMACOV project in Amazonas were evaluated and sociodemographic data, presence of comorbidities and clinical evolution of COVID-19 were collected. Results: Sample with 137 SLE patients, 76 with COVID-19 (Case group) and 61 healthy (Control group). There were comorbidities in 56.4% of the Case and 43.6% of the Control, the main ones being Arterial Hypertension and Obesity. The main laboratory finding was the elevation of inflammatory markers in the case, especially in those with associated diseases. Higher rates of hospitalizations, deaths and post-COVID-19 limitations occurred in those with comorbidities, even without statistical significance. Furthermore, the symptomatic period was longer in this group. Conclusion: The influence of comorbidities on the prognosis of patients with SLE and COVID-19 was small, as although data have shown that this group was more susceptible to worrying conditions, it was statistically similar to the group without comorbidities.